Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 ...

Recent label updates for Bristol Myers’ Camzyos should read positively for obstructive hypertrophic cardiomyopathy patients and physicians, as they could lead to greater categor ...

FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

J&J also raised its full-year revenue guidance to include sales of the psychiatric drug Caplyta, which the company got from ...

Cytokinetics Inc. (NASDAQ:CYTK) is a late-stage biopharmaceutical company that discovers, develops, and commercializes muscle activators and inhibitors as potential treatments for debilitating ...

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new ...

Shares of Bristol-Myers Squibb Company (NYSE: BMY) edged down 0.6% in premarket trading after announcing its Phase 3 ODYSSEY-HCM trial did not meet its primary endpoints. The study evaluated Camzyos ...

The result is a major disappointment for BMS as it effectively cuts the potential market for Camzyos in half. Sales of the ...